RT Journal Article
T1 Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
A1 Garcia-Sancho, Alejandro Martin
A1 Bellei, Monica
A1 Lopez-Parra, Miriam
A1 Gritti, Giuseppe
A1 Cortes, Maria
A1 Novelli, Silvana
A1 Panizo, Carlos
A1 Petrucci, Luigi
A1 Gutierrez, Antonio
A1 Dlouhy, Ivan
A1 Bastos-Oreiro, Mariana
A1 Sancho, Juan M
A1 Ramirez, Maria J
A1 Moraleda, Jose M
A1 Carrillo, Estrella
A1 Jimenez-Ubieto, Ana I
A1 Jarque, Isidro
A1 Orsucci, Lorella
A1 Garcia-Torres, Estefania
A1 Montalban, Carlos
A1 Dodero, Anna
A1 Arranz, Reyes
A1 De-Las-Heras, Natalia
A1 Pascual, Maria J
A1 Lopez-Jimenez, Javier
A1 Spina, Michelle
A1 Re, Alessandro
A1 De-Villambrosia, Sonia Gonzalez
A1 Bobillo, Sabela
A1 Federico, Massimo
A1 Caballero, Dolores
K1 Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
K1 Progression-Free Survival
K1 Drug Therapy
K1 Stem Cell Transplantation
K1 Lymphoma, Large-Cell, Anaplastic
AB Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies that mostly have poor prognoses with currently available treatments. Upfront consolidation with autologous stem cell transplantation (ASCT) is frequently carried out, but its efficacy has never been investigated in randomized trials. We designed a multicenter, international, retrospective study with the main objective of comparing progression-free survival and overall survival of patients with PTCL who underwent ASCT in complete remission (CR) after first-line chemotherapy with a control group who did not undergo ASCT. From the initial population of 286 registered patients, 174 patients with PTCL other than anaplastic large cell lymphoma, ALK-positive, deemed fit for ASCT at the time of diagnosis, and who were in CR or uncertain CR after induction therapy (CR1) were included in our analysis. one hundred and three patients underwent ASCT, whereas 71 did not, in most cases (n=53) because the physician decided against it. With a median follow-up of 65.5 months, progression-free survival was significantly better in the transplanted patients than in the non-transplanted group: 63% versus 48% at 5 years (P=0.042). Overall survival was significantly longer for ASCT patients in the subgroup with advanced stage at diagnosis (5-year overall survival: 70% vs. 50%, P=0.028). In the multivariate analysis, first-line ASCT was associated with significantly prolonged progression-free survival (HR=0.57, 95% CI: 0.35-0.93) and overall survival (HR=0.57, 95% CI: 0.33-0.99). In conclusion, our study supports the use of ASCT as a consolidation strategy for patients with PTCL in CR1. These results should be confirmed in a prospective randomized study.
PB Fondazione Ferrata Storti
YR 2022
FD 2022-03-24
LK http://hdl.handle.net/10668/20521
UL http://hdl.handle.net/10668/20521
LA en
NO García-Sancho AM, Bellei M, López-Parra M, Gritti G, Cortés M, Novelli S, et al. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. Haematologica. 2022 Nov 1;107(11):2675-2684
DS RISalud
RD Apr 11, 2025